Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised,...

Keywords

MedicinePlaceboImmunogenicityClinical endpointAdverse effectRandomized controlled trialInternal medicineIncidence (geometry)Clinical trialImmunologyAntibodyPathology

Affiliated Institutions

Related Publications

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson , Nadine Rouphael , Alicia T. Widge +34 more

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutra...

2020 New England Journal of Medicine 1581 citations

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu Bennet , Jayanthi Wolf , Rodrigo Laureano +1 more

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...

2020 Toxicologic Pathology 47 citations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack , Stephen J. Thomas , Nicholas Kitchin +26 more

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral...

2020 New England Journal of Medicine 14917 citations

Publication Info

Year: 2020
Type: article
Volume: 396
Issue: 10249
Pages: 479-488
Citations: 1278
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1278

OpenAlex

Cite This

APA Style

                            
                                
                                    Fengcai Zhu, 
                                
                                    Xu-Hua Guan, 
                                
                                    Yu-Hua Li
                                
                                et al.
                            
                            (2020). 
                            Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. 
                            The Lancet
                            , 396
                            (10249)
                            , 479-488.
                            https://doi.org/10.1016/s0140-6736(20)31605-6
                        

Identifiers

DOI: 10.1016/s0140-6736(20)31605-6